
    
      The primary objective of this study is to find out the response rate of twice weekly
      paclitaxel and cisplatin and weekly HDFL in recurrent or metastatic esophageal carcinoma
      patients who need palliative Chemotherapy. The secondary objectives include overall survival,
      progression-free survival, and toxicity.
    
  